7 September 2020 - Precision medicines rely on companion diagnostics to identify patient subgroups eligible for receiving the pharmaceutical product. 

Until recently, the Belgian public health payer, RIZIV-INAMI, assessed precision medicines and companion diagnostics separately for reimbursement decisions. As both components are considered co-dependent technologies, their assessment should be conducted jointly from a health technology assessment perspective. As of July 2019, a novel procedure was implemented accommodating for this joint assessment practice. 

The aim of this research was to formulate recommendations to improve the assessment in the novel procedure.

Read International Journal of Technology Assessment in Health Care article